The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis

Aim Atezolizumab plus bevacizumab (Atez/Bev) therapy is expected to have good therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However, the clinical indicators that predict therapeutic efficacy have not been established. We retrospectively investigated whether the neut...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology research 2023-06, Vol.53 (6), p.511-521
Hauptverfasser: Matoya, Sho, Suzuki, Takanori, Matsuura, Kentaro, Suzuki, Yuta, Okumura, Fumihiro, Nagura, Yoshihito, Sobue, Satoshi, Kuroyanagi, Keita, Kusakabe, Atsunori, Koguchi, Hiroki, Hasegawa, Izumi, Miyaki, Tomokatsu, Tanaka, Yoshito, Kondo, Hiromu, Kimura, Yoshihide, Ozasa, Atsushi, Kawamura, Hayato, Kuno, Kayoko, Fujiwara, Kei, Nojiri, Shunsuke, Kataoka, Hiromi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim Atezolizumab plus bevacizumab (Atez/Bev) therapy is expected to have good therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However, the clinical indicators that predict therapeutic efficacy have not been established. We retrospectively investigated whether the neutrophil‐to‐lymphocyte ratio (NLR) during Atez/Bev therapy could predict therapeutic efficacy. Method In total, 110 patients with HCC were enrolled; they were treated with Atez/Bev therapy and evaluated for their initial response by dynamic CT or MRI at least once between October 2020 and July 2022. Results Of the 110 patients with HCC at the initial evaluation, two (2%) showed a complete response (CR), 22 (20%) partial response (PR), 62 (56%) stable disease (SD), and 24 (21%) progressive disease (PD). The NLR at the start of the second course (NLR‐2c) increased from CR + PR to SD to PD. There was no significant association between the baseline NLR and the initial therapeutic response. Patients with CR + PR had lower NLR‐2c values than those with SD + PD (p 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13886